Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial

Next Previous
Trial Profile

Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiratricol (Primary)
  • Indications Allan-Herndon-Dudley syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms Triac; Triac Trial I; TRIAC-1
  • Sponsors Rare Thyroid Therapeutics

Most Recent Events

  • 13 Feb 2025 Results presented in an Egetis Therapeutics media release.
  • 13 Feb 2025 The EU approval is applicable to all 27 European Union member states, as well as Iceland, Norway, and Liechtenstein.
  • 13 Feb 2025 According to Egetis Therapeutics media release, the company announced that the European Commission (EC) has approved Emcitate (tiratricol) for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The approval of Emcitate is primarily based on Triac Trial I, supported by The Erasmus University Medical Center Cohort Study, and preliminary results of Triac Trial II.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top